A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating a Single Dose of Kamuvudine-8 (K8) for the Treatment of Patients with Diabetic Macular Edema

Grants and Contracts Details

StatusActive
Effective start/end date1/21/2310/30/24

Funding

  • Inflammasome Therapeutics Incorporated: $40,000.00